Confirmation of Q1 trading update

Summary by AI ^BETAClose X

CelLBxHealth plc has announced that it will release its trading update for the first quarter of 2026 in mid-May. The company, specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology, will provide an update on its performance.

Disclaimer*

CelLBxHealth PLC

30 April 2026

CelLBxHealth plc

("CelLBxHealth" or "the Company")

Confirmation of Q1 trading update

Guildford, UK and Plymouth Meeting, U.S. - 30 April 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, announces that it will provide a trading update for Q1 2026 in mid-May.

For further information:

CelLBxHealth plc

Peter Collins, Chief Executive Officer

Jan Groen, Executive Chairman

investor@cellbxhealth.com

via Walbrook PR

Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

+44 (0)20 7220 0500

Walbrook PR (Investor and Media Relations)

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

For more information, visit https://cellbxhealth.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END